Literature DB >> 12472552

Quality of life in epidermolysis bullosa.

H M Horn1, M J Tidman.   

Abstract

The quality of life of people with epidermolysis bullosa (EB) living in Scotland was assessed by postal questionnaire using the Dermatology Life Quality Index (DLQI) and the Children's Dermatology Life Quality Index (CDLQI). There were 143 people with EB simplex (EBS) and 99 individuals with non-Hallopeau--Siemens subtypes of dystrophic EB (DEB). A further six individuals had the severe Hallopeau--Siemens subtype of DEB (RDEB-HS). The overall response was 48% (EBS 52%, DEB 40% and RDEB-HS 83%). Impairment of quality of life (QOL) was greatest in those with RDEB-HS, mean scores (adults, 18; children, 22) exceeding those of any skin disorder previously assessed. The effect on QOL of EBS and other subtypes of DEB was similar to that of moderately severe psoriasis and eczema. EBS had a greater impact on QOL than the non-Hallopeau--Siemens subtypes of DEB (EBS adults mean score, 10.7; EBS children mean score, 15; DEB adults mean score, 7.5; DEB children mean score, 11.5).

Entities:  

Mesh:

Year:  2002        PMID: 12472552     DOI: 10.1046/j.1365-2230.2002.01121.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  29 in total

Review 1.  From marrow to matrix: novel gene and cell therapies for epidermolysis bullosa.

Authors:  Beau R Webber; Jakub Tolar
Journal:  Mol Ther       Date:  2015-03-24       Impact factor: 11.454

Review 2.  Psychosocial impact of inherited and autoimmune blistering diseases.

Authors:  Swaranjali V Jain; Dedee F Murrell
Journal:  Int J Womens Dermatol       Date:  2018-01-08

3.  Psychiatric symptoms and quality of life in patients affected by epidermolysis bullosa.

Authors:  Francesco Margari; Paola A Lecce; Wanda Santamato; Patrizia Ventura; Nicola Sportelli; Giuseppina Annicchiarico; Ernesto Bonifazi
Journal:  J Clin Psychol Med Settings       Date:  2010-12

Review 4.  Quality of life in patients with bullous dermatoses.

Authors:  Deshan F Sebaratnam; James R McMillan; Victoria P Werth; Dédée F Murrell
Journal:  Clin Dermatol       Date:  2012 Jan-Feb       Impact factor: 3.541

5.  Adopting a Sustainable Community of Practice Model when Developing a Service to Support Patients with Epidermolysis Bullosa (EB): A Stakeholder-Centered Approach.

Authors:  Rosemary Joan Gowran; Avril Kennan; Siobhán Marshall; Irene Mulcahy; Sile Ní Mhaille; Sarah Beasley; Mark Devlin
Journal:  Patient       Date:  2015-02       Impact factor: 3.883

6.  A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis bullosa simplex.

Authors:  Jodi Y So; Shivali Fulchand; Christine Y Wong; Shufeng Li; Jaron Nazaroff; Emily S Gorell; Mark P de Souza; Dedee F Murrell; Joyce M Teng; Albert S Chiou; Jean Y Tang
Journal:  Orphanet J Rare Dis       Date:  2022-07-15       Impact factor: 4.303

Review 7.  Toward Combined Cell and Gene Therapy for Genodermatoses.

Authors:  Laura De Rosa; Maria Carmela Latella; Alessia Secone Seconetti; Cecilia Cattelani; Johann W Bauer; Sergio Bondanza; Michele De Luca
Journal:  Cold Spring Harb Perspect Biol       Date:  2020-05-01       Impact factor: 10.005

Review 8.  Darier's disease: hopes and challenges.

Authors:  Laurence Hulatt; Susan Burge
Journal:  J R Soc Med       Date:  2003-09       Impact factor: 18.000

Review 9.  Advances in understanding and treating dystrophic epidermolysis bullosa.

Authors:  Michael J Vanden Oever; Jakub Tolar
Journal:  F1000Prime Rep       Date:  2014-05-06

10.  Quality of life in Swedish children with congenital ichthyosis.

Authors:  Agneta Gånemo
Journal:  Dermatol Reports       Date:  2010-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.